Isao Okayasu Selected Research

Therapeutics

6/2020	Positive correlation of expression of L-type amino-acid transporter 1 with colorectal tumor progression and prognosis: Higher expression in sporadic colorectal tumors compared with ulcerative colitis-associated neoplasia.
1/2015	L-amino acid transporter 1 may be a prognostic marker for local progression of prostatic cancer under expectant management.
10/2014	High expression of L-type amino acid transporter 1 as a prognostic marker in bile duct adenocarcinomas.
6/2012	Development of ulcerative colitis and its associated colorectal neoplasia as a model of the organ-specific chronic inflammation-carcinoma sequence.
5/2011	High expression of L-type amino-acid transporter 1 (LAT1) in gastric carcinomas: comparison with non-cancerous lesions.
8/2010	Newly developed antibiotic combination therapy for ulcerative colitis: a double-blind placebo-controlled multicenter trial.
7/2010	Proteomic study of sera from patients with bladder cancer: usefulness of S100A8 and S100A9 proteins.
10/2009	Heparin-induced thrombocytopenia with multiple organized thrombi accompanied by unusual cholesterin deposition: autopsy case after long-term follow up.
8/2009	Liquid-based preparation for endometrial cytology--usefulness for predicting the prognosis of endometrial carcinoma preoperatively.
7/2006	[8-month neoadjuvant hormonal therapy before radical prostatectomy for high-risk prostate cancer].

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Isao Okayasu Research Topics

Disease

38	Neoplasms (Cancer) 06/2020 - 02/2002
25	Ulcerative Colitis 05/2022 - 08/2002
25	Carcinoma (Carcinomatosis) 02/2018 - 03/2002
15	Adenocarcinoma 10/2014 - 02/2002
10	Carcinogenesis 02/2011 - 04/2002
9	Inflammation (Inflammations) 02/2018 - 07/2003
9	Endometrial Neoplasms (Endometrial Cancer) 02/2011 - 01/2003
7	Colitis 01/2016 - 10/2002
6	Colorectal Neoplasms (Colorectal Cancer) 08/2020 - 05/2007
5	Prostatic Neoplasms (Prostate Cancer) 07/2021 - 07/2005
5	Adenoma (Adenomas) 05/2011 - 04/2002
4	Infections 11/2005 - 01/2003
3	Neoplasm Metastasis (Metastasis) 12/2013 - 07/2006
3	Astrocytoma (Pilocytic Astrocytoma) 01/2010 - 07/2004
3	Glioblastoma (Glioblastoma Multiforme) 01/2010 - 07/2004
3	Stomach Neoplasms (Stomach Cancer) 12/2009 - 08/2006
3	Lung Neoplasms (Lung Cancer) 10/2009 - 02/2004
2	Breast Neoplasms (Breast Cancer) 09/2021 - 01/2018
2	Lymphatic Metastasis 09/2021 - 07/2015
2	Endometrioid Carcinoma 05/2014 - 07/2004
2	Hemangiosarcoma (Angiosarcoma) 12/2013 - 03/2010
2	Papillary Carcinoma 05/2013 - 04/2002
2	Fibrosis (Cirrhosis) 02/2013 - 01/2011
2	Abscess 06/2012 - 05/2009
2	Rectal Neoplasms (Rectal Cancer) 03/2011 - 12/2007
2	Ulcer 12/2010 - 01/2009
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 02/2010 - 10/2008
2	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 02/2010 - 10/2009
2	Neuroendocrine Tumors (Neuroendocrine Tumor) 10/2009 - 10/2004
2	Diarrhea 12/2007 - 11/2002
2	Mycoses (Diseases, Fungus) 01/2006 - 11/2003
2	Small Cell Carcinoma 10/2004 - 02/2004
1	Triple Negative Breast Neoplasms 09/2021
1	Hypoxia (Hypoxemia) 08/2020
1	Immune System Diseases (Immune Disorders) 01/2018
1	Lung Diseases (Lung Disease) 01/2017
1	Asthma (Bronchial Asthma) 01/2017

Drug/Important Bio-Agent (IBA)

13	Proteins (Proteins, Gene)FDA Link 06/2020 - 03/2002
13	Biomarkers (Surrogate Marker)IBA 06/2020 - 11/2006
10	Amino Acid Transport Systems (Amino Acid Transporter)IBA 09/2021 - 01/2009
8	beta CateninIBA 04/2011 - 01/2003
7	Formaldehyde (Formol)FDA Link 07/2010 - 01/2006
7	ParaffinIBA 07/2010 - 01/2006
6	ProstaglandinsIBA 05/2022 - 07/2014
6	Cyclin D1IBA 03/2010 - 05/2004
5	11 alpha- hydroxy- 9,15- dioxo- 2,3,4,5,20- pentanor- 19- carboxyprostanoic acidIBA 01/2017 - 01/2014
5	Dextran SulfateIBA 01/2016 - 10/2002
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 05/2013 - 07/2004
4	Messenger RNA (mRNA)IBA 03/2011 - 02/2004
4	Cyclin-Dependent Kinase Inhibitor p16IBA 03/2010 - 11/2006
4	Cyclin AIBA 08/2009 - 07/2004
4	DNA (Deoxyribonucleic Acid)IBA 03/2007 - 02/2003
4	EnzymesIBA 11/2006 - 01/2003
3	Progesterone Receptors (Progesterone Receptor)IBA 09/2021 - 01/2003
3	Dinoprostone (PGE2)FDA Link 01/2017 - 07/2014
3	AzoxymethaneIBA 01/2016 - 11/2002
3	Estrogen ReceptorsIBA 05/2014 - 03/2004
3	Estrogens (Estrogen)FDA Link 12/2013 - 11/2007
3	Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA 05/2013 - 01/2011
3	Monoclonal AntibodiesIBA 05/2011 - 01/2009
3	Irinotecan (Camptosar)FDA LinkGeneric 03/2011 - 12/2007
3	MucinsIBA 12/2010 - 01/2008
3	Tumor Suppressor Protein p14ARF (p14ARF)IBA 09/2007 - 07/2004
3	Chromogranin AIBA 08/2006 - 02/2004
2	Thymidine KinaseIBA 07/2021 - 11/2006
2	Immunoglobulin A (IgA)IBA 01/2018 - 01/2016
2	AcidsIBA 01/2016 - 03/2006
2	Immunoglobulin G (IgG)IBA 01/2016 - 01/2003
2	Indicators and Reagents (Reagents)IBA 10/2014 - 11/2009
2	CytokinesIBA 06/2012 - 05/2009
2	Hematoxylin (Haematoxylon)IBA 09/2011 - 05/2004
2	Eosine Yellowish-(YS) (Eosin)IBA 09/2011 - 05/2004
2	AntigensIBA 04/2011 - 08/2002
2	Complementary DNA (cDNA)IBA 03/2011 - 11/2007
2	Butyric Acid (Butanoic Acid)IBA 03/2011 - 03/2006
2	SodiumIBA 12/2010 - 11/2002
2	Anti-Bacterial Agents (Antibiotics)IBA 08/2010 - 11/2005
2	NF-kappa B (NF-kB)IBA 01/2010 - 05/2009
2	Transcription Factors (Transcription Factor)IBA 01/2010 - 05/2004
2	Cadherins (E-Cadherin)IBA 06/2009 - 03/2007
2	Cyclin EIBA 01/2006 - 07/2004
2	Coloring Agents (Dyes)IBA 11/2004 - 01/2003
2	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 07/2004 - 04/2002
2	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 07/2004 - 04/2002
2	alpha-Fetoproteins (alpha-Fetoprotein)IBA 03/2004 - 02/2002
1	human ERBB2 proteinIBA 09/2021
1	Ganciclovir (Cytovene)FDA LinkGeneric 07/2021
1	Carbonic Anhydrases (Carbonic Anhydrase)IBA 08/2020
1	ProteomeIBA 02/2018
1	ThioredoxinsIBA 02/2018
1	PeroxiredoxinsIBA 02/2018
1	7- hydroxy- 5,11- dioxotetranorprostane- 1,16- dioic acidIBA 01/2018

Therapy/Procedure

13	Therapeutics 06/2020 - 01/2003
5	Drug Therapy (Chemotherapy) 01/2014 - 11/2003
5	Lasers (Laser) 12/2009 - 10/2003
2	Chemoradiotherapy 03/2011 - 12/2007
2	Adjuvant Chemotherapy 11/2010 - 12/2009
2	Gastrectomy 12/2009 - 02/2002
2	Intraperitoneal Injections 11/2006 - 11/2002
2	Oral Administration 01/2003 - 11/2002